SEGMENTED INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132
COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)
GROSS (LOSS)/PROFIT		20,236			899,567			-			919,803
OTHER INCOME		6,617			146,720			3			153,340
OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)
FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)
(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)
Tax expense		-			(22,792	)		-			(22,792	)
NET (LOSS)/PROFIT	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

	BioNexus Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2021
REVENUE	$	1,504,064		$	8,613,232		$	-		$	10,117,296
COST OF REVENUE		(1,057,314	)		(7,270,208	)		-			(8,327,522	)
GROSS PROFIT		446,750			1,343,024			-			1,789,774
OTHER INCOME		5,335			154,429			-			159,764
OPERATING EXPENSES
General and administrative		(115,758	)		(843,620	)		(135,396	)		(1,094,774	)
FINANCE COSTS		(3,265	)		(5,722	)		-			(8,987	)
PROFIT/(LOSS) BEFORE TAX		333,062			648,111			(135,396	)		845,777
Tax expense		(38,068	)		(145,381	)		-			(183,449	)
NET PROFIT/(LOSS)	$	294,994		$	502,730		$	(135,396	)	$	662,328

	As of September 30, 2022 and December 31, 2021
	Total Assets				Total Liabilities
	2022		2021		2022		2021
BGLC & Bionexus	$	870,929	$	1,167,214	$	64,914	$	121,586
Chemrex		6,927,307		8,407,176		1,309,668		2,273,025
TOTAL		7,798,236		9,574,390		1,374,582		2,394,611